Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 3/20 | 0.50 |
| ▸ | EGFR | P00533 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.45 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1070256 | 0.90 | ALOX5 (0.53) | ALOX5EGFRLMNAL3MBTL1MAOB | |
| SCHEMBL1069511 | 0.86 | LMNA (0.60) | ALOX5EGFRLMNAL3MBTL1ALDH1A1 | |
| SCHEMBL22304944 | 0.85 | ALDH1A1 (0.52) | LMNAALDH1A1HSD17B10 | |
| SCHEMBL1069341 | 0.84 | LTA4H (0.53) | ALOX5EGFRLTA4H | |
| SCHEMBL1071486 | 0.84 | ALOX5 (0.49) | ALOX5EGFRLMNAL3MBTL1 | |
| SCHEMBL1070343 | 0.83 | ALOX5 (0.48) | ALOX5EGFRLMNAL3MBTL1ALDH1A1 | |
| SCHEMBL6123064 | 0.81 | PRKCA (0.51) | ALOX5EGFRMAOBLTA4H | |
| SCHEMBL6123263 | 0.81 | LMNA (0.46) | ALOX5EGFRLMNAL3MBTL1ALDH1A1 | |
| SCHEMBL6122799 | 0.81 | PRKCA (0.53) | ALOX5EGFRMAOB | |
| SCHEMBL6123338 | 0.80 | LMNA (0.48) | ALOX5EGFRLMNAL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150183722-A1 | Process for the Preparation of O-Desmethyl Venlafaxine and Intermediate for Use Therein | CIPLA LIMITED (IN) | 2015-07-02 | — | — | US | disclosed |
| US-9012689-B2 | Process for the preparation of O-desmethyl venlafaxine and intermediate for use therein | CIPLA LIMITED (IN) | 2015-04-21 | — | — | US | disclosed |
| US-20120157544-A1 | Process for the Preparation of O-Desmethyl Venlafaxine and Intermediate for Use Therein | CIPLA LIMITED (IN) | 2012-06-21 | — | — | US | disclosed |
| EP-2454228-A2 | PROCESS FOR THE PREPARATION OF O-DESMETHYL VENLAFAXINE AND INTERMEDIATE FOR USE THEREIN | CIPLA LIMITED (IN) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011007136-A2 | PROCESS FOR THE PREPARATION OF O-DESMETHYL VENLAFAXINE AND INTERMEDIATE FOR USE THEREIN | CIPLA LIMITED (IN) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183722-A1 | Process for the Preparation of O-Desmethyl Venlafaxine and Intermediate for Use Therein | SLC6A2, SLC6A3, MAOA | ALOX5 1190/4885EGFR 2901/4885LMNA 1856/4885 |
| US-20120157544-A1 | Process for the Preparation of O-Desmethyl Venlafaxine and Intermediate for Use Therein | SLC6A2, SLC6A3, MAOA | ALOX5 1190/4885EGFR 2901/4885LMNA 1856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.